Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC

NCT03300115 is registered in ClinicalTrials.gov with Hangzhou ACEA Pharmaceutical Research Co., Ltd. as lead sponsor.

NCT NCT03300115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03300115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC
Lead sponsor
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
May 18, 2017
Completion date
December 17, 2020
Enrollment
222 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non-small cell lung cancer